-
Ferring and CDI sign agreement granting Ferring exclusive marketing rights to VSL#3® in Europe and Canada
in Uncategorized onFerring Pharmaceuticals and CD Investments (CDI) announced today that they have signed an agreement granting Ferring exclusive European marketing…
0 -
Waking up to go to the toilet is the number one cause of a poor night’s sleep, say experts on World Sleep Day
in Uncategorized onOn World Sleep Day sleep experts encourage people to understand the value of healthy and solid sleep…
-
Ferring collaborates with ICF on development of a potential new treatment for anal fissures with a focus on improving quality of care for IBD patients
in Uncategorized onFerring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research…
-
Ferring acquires ex-U.S. assets and rights for Vitaros® (alprostadil cream), Apricus’ on-demand topical cream for erectile dysfunction
in Uncategorized onFerring Pharmaceuticals today announced an agreement with Apricus Biosciences, Inc. (Nasdaq:APRI), granting Ferring global…
-
Ferring Announces Recipients of Innovation Grants Program 2016-2017
in Uncategorized onFerring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute…
-
Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement
in Uncategorized onFerring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive…
-
Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
in Uncategorized onFerring Pharmaceuticals and Enteris BioPharma, Inc. announced today that the companies have entered…
-
Ferring partners with Intralytix to develop bacteriophage treatments for conditions associated with the microbiome and drug-resistant bacteria
in Uncategorized onFerring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments…
-
Ferring and IMAB sign licensing agreement granting IMAB exclusive rights in Asia to olamkicept for the treatment of autoimmune disease
in Uncategorized onFerring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights…
-
Ferring receives EU approval for REKOVELLE® (follitropin delta)
in Uncategorized onFerring Pharmaceuticals announced today that the European Commission (EC) has granted marketing authorisation for REKOVELLE®…
Author archive for pulse
Articles by: pulse